Literature DB >> 11287451

Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.

H Jernström, D Vesprini, H L Bradlow, S A Narod.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11287451     DOI： 10.1093/jnci/93.7.554

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Genetic variation of the CYP17 and susceptibility to endometrial cancer: a meta-analysis.

Authors:  Jun Xu; Xiao Lin; Haoping Zhu; Zhiling Zhang; Baohua Yang
Journal:  Mol Biol Rep       Date:  2013-05-07       Impact factor: 2.316

2.  CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.

Authors:  Emaculate Verla-Tebit; Shan Wang-Gohrke; Jenny Chang-Claude
Journal:  Breast Cancer Res       Date:  2005-04-12       Impact factor: 6.466

3.  CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study.

Authors:  Jiun-Horng Chang; Dorota M Gertig; Xiaoqing Chen; Gillian S Dite; Mark A Jenkins; Roger L Milne; Melissa C Southey; Margaret R E McCredie; Graham G Giles; Georgia Chenevix-Trench; John L Hopper; Amanda B Spurdle
Journal:  Breast Cancer Res       Date:  2005-05-12       Impact factor: 6.466

4.  CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors.

Authors:  Christine B Ambrosone; Kirsten B Moysich; Helena Furberg; Jo L Freudenheim; Elise D Bowman; Sabrina Ahmed; Saxon Graham; John E Vena; Peter G Shields
Journal:  Breast Cancer Res       Date:  2003-01-29       Impact factor: 6.466
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.